Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › anti-thymocyte globulin

anti-thymocyte globulin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of anti-thymocyte globulin

35 trials tracked of anti-thymocyte globulin: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 7 citations.

35Trials tracked
4Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 29 Other / NA 2
  1. Phase 4 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation Completed · 7 cited
  2. Phase 4 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance Completed
  3. Phase 3 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Completed
  4. Phase 3 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed
  5. Phase 2 Autologous and Allogeneic Transplant for Relapsed Lymphoma Completed
  6. Phase 2 Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant Completed
Show 29 more trials
  1. Phase 2 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders Completed
  2. Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
  3. Phase 2 Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed
  4. Phase 2 Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia Completed
  5. Phase 2 Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders Completed
  6. Phase 2 Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs Completed
  7. Phase 2 Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies Completed
  8. Phase 2 Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia Completed
  9. Phase 2 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Completed
  10. Phase 2 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Completed
  11. Phase 2 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Completed
  12. Phase 2 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed
  13. Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Completed
  14. Phase 2 Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant Completed
  15. Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  16. Phase 2 CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Completed
  17. Phase 2 Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia Completed
  18. Phase 2 CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Completed
  19. Phase 2 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed
  20. Phase 2 Scleroderma Treatment With Autologous Transplant (STAT) Study Completed
  21. Phase 2 Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Completed
  22. Phase 2 Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission Completed
  23. Phase 2 Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia Completed
  24. Phase 2 Allogeneic Transplantation From Related Haploidentical Donors Completed
  25. Phase 2 Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer Completed
  26. Phase 2 Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Completed
  27. Phase 2 Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG Completed
  28. N/A Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders Completed
  29. N/A Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
TDM-Based ATG Dosing Improves GRFS in Haploidentical Transplant
Drug Pipeline RCT
TDM-Based ATG Dosing Improves GRFS in Haploidentical Transplant Trial shows tailored dosing improves graft-versus-host disease outcomes
TDM-based ATG dosing boosted 365-day GRFS to 66.7% vs 50% with fixed dosing in haploidentical transplant, cutting chronic GVHD and infection…
A new dosing strategy for ATG medication may improve survival and reduce severe complications for patients undergoing specific stem cell tra…
Oct 12, 2026
Immune reconstitution rates and survival outcomes in patients with myeloid malignancies receiving matched unrelated donor allo-HCT
Drug Pipeline Cohort
Immune reconstitution rates and survival outcomes in patients with myeloid malignancies receiving matched unrelated donor allo-HCT Better immune recovery links to longer survival after stem cell transplant
This retrospective bi-centric study evaluated immune reconstitution and survival in 252 patients with myeloid malignancies undergoing matche…
New data shows immune recovery matters most for survival after bone marrow transplants. One drug may help rebuild defenses faster.
Frontiers Apr 29, 2026